摘要
全球哮喘防治创议(GINA)不断优化哮喘治疗策略,提出了抗炎缓解药物(AIR)与维持和缓解治疗(MART)的概念。AIR主要包括布地奈德-福莫特罗、倍氯米松-福莫特罗以及吸入性糖皮质激素(ICS)-短效β2受体激动剂。MART指使用同一种ICS-福莫特罗作为维持治疗和缓解药物的治疗方案。目前,AIR和MART用于6岁及以上儿童、青少年及成人哮喘的治疗。本文对GINA 2025中儿童AIR和MART相关内容进行解读,介绍其在儿童哮喘治疗中的应用及在哮喘行动计划中的使用,旨在为临床医师提供参考,以优化儿童哮喘的治疗。
The Global Initiative for Asthma(GINA)continues to optimize asthma treatment strategies and has introduced the concepts of anti-inflammatory reliever(AIR)and maintenance and reliever therapy(MART).AIR mainly includes Budesonide-Formoterol,Beclomethasone-Formoterol,and inhaled corticosteroids(ICS)combined with short-acting beta2-agonist.MART refers to a treatment regimen that utilizes the same ICS-Formoterol combination for both maintenance and reliever therapy.Currently,AIR and MART are recommended for the treatment of asthma in children aged 6 years and older,adolescents and adults.This article provides an interpretation of the pediatric AIR and MART content in GINA 2025,highlighting their clinical application in pediatric asthma treatment and their role in asthma action plans,with the aim of providing a reference for clinicians to optimize the treatment of pediatric asthma.
作者
韩鹏
郑跃杰
鲍燕敏
申昆玲
Han Peng;Zheng Yuejie;Bao Yanmin;Shen Kunling(Department of Respiratory,Shenzhen Children′s Hospital,Shenzhen 518038,China;Department of Respiratory,Beijing Children′s Hospital,Capital Medical University,China National Clinical Research Center of Respiratory Diseases,National Center for Children′s Health,Beijing 100045,China)
出处
《中华实用儿科临床杂志》
北大核心
2025年第11期817-820,共4页
Chinese Journal of Applied Clinical Pediatrics
基金
广东省高水平医院建设专项经费(粤府办2021-6)。
关键词
哮喘
全球哮喘防治创议
抗炎缓解药物
维持和缓解治疗
儿童
Asthma
Global Initiative for Asthma
Anti-inflammatory reliever
Maintenance and reliever therapy
Child
